Close Menu

NEW YORK – Guardant Health reported after the close of the market on Thursday that its first quarter 2019 revenues were up 84 percent year over year.

The liquid biopsy firm reported total revenues of $67.5 million compared to $36.7 million in Q1 2019, easily beating the consensus Wall Street estimate of $56.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.